ADR Biomedical HoldingsTSE:3750 -1.23%30 Gross Margin % is 13.09% as of Mar. 2026, which is 77% below its 10-year median of 56.24. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.42 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 730 Biotechnology companies, ADR Biomedical Holdings ranks worse than 83.29% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ADR Biomedical Holdings had a gross margin of 13.09% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ADR Biomedical Holdings Gross Margin % Related Terms
ADR Biomedical Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3750 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, ADR Biomedical Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ADR Biomedical Holdings (TSE:3750) has a Gross Margin % of 13.09% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on ADR Biomedical Holdings and its competitors. This is 77% below median its historical median of 56.24. According to the industry distribution chart, ADR Biomedical Holdings ranks #608 out of 730 companies in the Biotechnology industry, placing it in the top 83.3%.
Is ADR Biomedical Holdings' Gross Margin % too high?
ADR Biomedical Holdings' current Gross Margin % of 13.09% is 77% below median its 10-year median of 56.24. The Biotechnology industry median Gross Margin % is 60.91. ADR Biomedical Holdings' value of 13.09% is 78.5% below this industry median. Based on the distribution chart, ADR Biomedical Holdings ranks #608 out of 730 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #608 out of 730 companies for Gross Margin %. This places ADR Biomedical Holdings in the lower half of its industry. The industry median Gross Margin % is 60.91. ADR Biomedical Holdings' value of 13.09% is 78.5% below this benchmark. While the company's 10-year median is 56.24 vs. the industry median of 60.91, ADR Biomedical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADR Biomedical Holdings's current Gross Margin % of 13.09% is 78.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ADR Biomedical Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADR Biomedical Holdings's current Gross Margin % is 13.09%, which is 77% below median its own 10-year median of 56.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.42, compared to a current price of 円805.00 — trading 1891.6% above its estimated fair value. The current Gross Margin % is 13.09%, which is 77% below median its 10-year median of 56.24 and 78.5% below the Biotechnology industry median of 60.91. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Gross Margin % is 13.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円805.00 is trading 1891.6% above its estimated GF Value™ of 円40.42.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
Gross Margin %: 13.09% (77% below median its 10-year median of 56.24)
GF Value™: 円40.42 vs. price of 円805.00 (1891.6% above fair value)
Industry Position: 78.5% below the Biotechnology median (#608 of 730)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score
Get the complete analysis for TSE:3750
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
